Sinem Namdaroğlu

Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series

Background Renal impairment is a frequent and adverse prognostic factor in multiple myeloma (MM), with dialysis-dependent patients largely excluded from pivotal trials of B-cell maturation antigen (BCMA)-directed therapies. Elranatamab, a BCMA×CD3 bispecific antibody, has demonst...

Fresh (Non-cryopreserved) autologous stem cell transplantation in multiple myeloma: Faster engraftment and reduced hospitalization

Background Cryopreserved autologous hematopoietic stem cell transplantation using dimethyl sulfoxide is standard in multiple myeloma but it is associated with infusion-related toxicity and high cost. This study aimed to evaluate the feasibility, safety, and outcomes of dimethyl s...